Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer

Expert Opinion on Biological Therapy

Volumn 7, Issue 7, 2007, Pages 997-1007

  Ramqvist, Torbjörn ^a   Andreasson, Kalle ^a   Dalianis, Tina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer; Immunotherapy; Vaccine; Virus; Virus like particles

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VACCINE; WART VIRUS VACCINE;

BACULOVIRUS; CANCER; DENGUE; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INSECT CELL; NONHUMAN; REVIEW; UTERINE CERVIX CANCER; VACCINATION; VIRUS GENE; VIRUS INFECTION; VIRUS LIKE AGENT; WART VIRUS;

AIDS VACCINES; ANIMALS; CAPSID PROTEINS; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; GENE THERAPY; HEPATITIS B VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PAPILLOMAVIRUS VACCINES; VACCINATION; VIRION;

ESCHERICHIA COLI; HEXAPODA; HUMAN PAPILLOMAVIRUS; MAMMALIA;

EID: 34547641767     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.7.997     Document Type: Review

References (86)

1. SPECK LM, TYRING SK: Vaccines for the prevention of human papillomavirus infections. Skin Therapy Lett. (2006) 11(6):1-3.
2. SCHMIEDESKAMP MR, KOCKLER DR: Human papillomavirus vaccines. Ann. Pharmacother. (2006) 40(7-8):1344-1352.
3. LIN YY, ALPHS H, HUNG CF, RODEN RB, WU TC: Vaccines against human papillomavirus. Front. Biosci. (2007) 12:246-264. A paper demonstrating the efficiency of VLPs carrying tumor antigens as vaccines against non-viral tumors.
4. TEGERSTEDT K, LINDENCRONA JA, CURCIO C et al.: A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res. (2005) 65(13):5953-5957.
5. KIMCHI-SARFATY C, GOTTESMAN MM: SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy. Curr. Pharm. Biotechnol. (2004) 5(5):451-458. An early paper demonstrating the ability to induce autoantibodies using conjugated VLPs.
6. CHACKERIAN B, LOWY DR, SCHILLER JT: Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. (2001) 108(3):415-423.
7. MAURER P, JENNINGS GT, WILLERS J et al.: A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. (2005) 35(7):2031-2040.
8. PALKOVA Z, ADAMEC T, LIEBL D, STOKROVA J, FORSTOVA J: Production of polyomavirus structural protein VP1 in yeast cells and its interaction with cell structures. FEBS Lett. (2000) 478(3):281-289.
9. FORSTOVA J, KRAUZEWICZ N, WALLACE S et al.: Cooperation of structural proteins during late events in the life cycle of polyomavirus. J. Virol. (1993) 67(3):1405-1413.
10. SALUNKE DM, CASPAR DL, GARCEA RL: Self-assembly of purified polyomavirus capsid protein VP1. Cell (1986) 46(6):895-904.
11. SZECSI J, BOSON B, JOHNSSON P et al.: Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol. J.(2006) 3:70.
12. LATHAM T, GALARZA JM: Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. (2001) 75(13):6154-6165. A clinical trial demonstrating the efficiency of a quadruple HPV VLP vaccine.
13. CHEN XS, CASINI G, HARRISON SC, GARCEA RL: Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J. Mol. Biol. (2001) 307(1):173-182. The first major clinical trial of a HPV VLP-based vaccine.
14. BRINKMAN M, WALTER J, GREIN S et al.: Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma. Cancer Immunol. Immunother. (2005) 54(6):611-622.
15. VILLA LL, COSTA RL, PETTA CA et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol. (2005) 6(5):271-278.
16. KOUTSKY LA, AULT KA, WHEELER CM et al.: A controlled trial of a human papillomavirus Type 16 vaccine. N. Engl. J. Med. (2002) 347(21):1645-1651.
17. MCALEER WJ, BUYNAK EB, MAIGETTER RZ et al.: Human hepatitis B vaccine from recombinant yeast. Nature (1984) 307(5947):178-180.
18. DOAN LX, LI M, CHEN C, YAO Q: Virus-like particles as HIV-1 vaccines. Rev. Med. Virol. (2005) 15(2):75-88.
19. GALARZA JM, LATHAM T, CUPO A: Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral. Immunol. (2005) 18(1):244-251.
20. BERTOLOTTI-CIARLET A, CIARLET M, CRAWFORD SE, CONNER ME, ESTES MK: Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine (2003) 21(25-26):3885-3900.
21. WARFIELD KL, SWENSON DL, DEMMIN G, BAVARI S: Filovirus-like particles as vaccines and discovery tools. Expert Rev. Vaccines (2005) 4(3):429-440.
22. TACKET CO, SZTEIN MB, LOSONSKY GA, WASSERMAN SS, ESTES MK: Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. (2003) 108(3):241-247.
23. BALL JM, GRAHAM DY, OPEKUN AR et al.: Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology (1999) 117(1):40-48.
24. HAMMONDS J, CHEN X, FOUTS T et al.: Induction of neutralizing antibodies against human immunodeficiency virus Type 1 primary isolates by Gag-Env pseudovirion immunization. J. Virol. (2005) 79(23):14804- 14814.
25. VLASTOS A, ANDREASSON K, TEGERSTEDT K et al.: VP1 pseudocapsids, but not a glutathione-S-transferase VP1 fusion protein, prevent polyomavirus infection in a T-cell immune deficient experimental mouse model. J. Med. Virol. (2003) 70(2):293-300.
26. AMES A, GRAVITT P: Human papillomavirus vaccine update. Curr. Infect. Dis. Rep. (2007) 9(2):151-158.
27. HARPER DM, FRANCO EL, WHEELER CM et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 367(9518):1247-1255.
28. HARRO CD, PANG YY, RODEN RB et al.: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. (2001) 93(4):284-292.
29. PINTO LA, VISCIDI R, HARRO CD et al.: Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology (2006) 353(2):451-462.
30. LIU WJ, GISSMANN L, SUN XY et al.: Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus Type 1 virions. Virology (1997) 227(2):474-483.
31. RODEN RB, YUTZY WHT, FALLON R et al.: Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology (2000) 270(2):254-257.
32. PUMPENS P, RAZANSKAS R, PUSHKO P et al.: Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes. Intervirology (2002) 45(1):24-32.
33. FITZSIMONS D, FRANCOIS G, HALL A et al.: Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine (2005) 23(32):4158-4166.
34. KAO JH, CHEN DS: Global control of hepatitis B virus infection. Lancet Infect. Dis. (2002) 2(7):395-403.
35. YOUNG KR, MCBURNEY SP, KARKHANIS LU, ROSS TM: Virus-like particles: designing an effective AIDS vaccine. Methods (2006) 40(1):98-117.
36. CIMARELLI A, DARLIX JL: Assembling the human immunodeficiency virus Type 1. Cell Mol. Life Sci.(2002) 59(7):1166-1184.
37. MCBURNEY SP, YOUNG KR, ROSS TM: Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology (2007) 358(2):334-346.
38. LINDENBURG CE, STOLTE I, LANGENDAM MW et al.: Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine (2002) 20(17-18):2343-2347.
39. FEHR T, SKRASTINA D, PUMPENS P, ZINKERNAGEL RM: T cell-independent Type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl. Acad. Sci. USA (1998) 95(16):9477- 9481.
40. GEDVILAITE A, FROMMEL C, SASNAUSKAS K et al.: Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Virology (2000) 273(1):21-35.
41. WAKABAYASHI MT, DA SILVA DM, POTKUL RK, KAST WM: Comparison of human papillomavirus Type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology (2002) 45(4-6):300-307.
42. AMEXIS G, YOUNG NS: Parvovirus B19 empty capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus. J. Infect. Dis. (2006) 194(6):790-794.
43. MIHAILOVA M, BOOS M, PETROVSKIS I et al.: Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine (2006) 24(20):4369-4377.
44. WOO WP, DOAN T, HERD KA, NETTER HJ, TINDLE RW: Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. J. Virol. (2006) 80(8):3975- 3984.
45. CHACKERIAN B, LENZ P, LOWY DR, SCHILLER JT: Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J. Immunol. (2002) 169(11):6120-6126.
46. SLUPETZKY K, GAMBHIRA R, CULP TD et al.: A papillomavirus-like particle (VLP) vaccine displaying HPV 16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2007) 25(11):2001-2010.
47. GELDMACHER A, SKRASTINA D, BORISOVA G et al.: A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies. Vaccine (2005) 23(30):3973- 3983.
48. SADEYEN JR, TOURNE S, SHKRELI M, SIZARET PY, COURSAGET P: Insertion of a foreign sequence on capsid surface loops of human papillomavirus Type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope. Virology (2003) 309(1):32-40.
49. MULLER M, ZHOU J, REED TD et al.: Chimeric papillomavirus-like particles. Virology (1997) 234(1):93-111.
50. MUNGER K, HOWLEY PM: Human papillomavirus immortalization and transformation functions. Virus Res. (2002) 89(2):213-228.
51. JOCHMUS I, SCHAFER K, FAATH S, MULLER M, GISSMANN L: Chimeric virus-like particles of the human papillomavirus Type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch. Med Res. (1999) 30(4):269-274.
52. KAUFMANN AM, NIELAND J, SCHINZ M et al.: HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int. J. Cancer (2001) 92(2):285-293.
53. GEDVILAITE A, ZVIRBLIENE A, STANIULIS J et al.: Segments of puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice. Viral Immunol. (2004) 17(1):51-68.
54. GREENSTONE HL, NIELAND JD, DE VISSER KE et al.: Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA (1998) 95(4):1800-1805.
55. SLAMONDJ, CLARK GM, WONG SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235(4785):177-182.
56. KIESSLING R, WEI WZ, HERRMANN F et al.: Cellular immunity to the Her-2/neu protooncogene. Adv. Cancer Res. (2002) 85:101-144.
57. PANNELLINI T, FORNI G, MUSIANI P: Immunobiology of her-2/neu transgenic mice. Breast Dis. (2004) 20:33-42. The first paper demonstrating activation of DCs by HPV VLPs.
58. NIELAND JD, DA SILVA DM, VELDERS MP et al.: Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J. Cell Biochem. (1999) 73(2):145-152.
59. AMBUHLPM, TISSOT AC, FULURIJA A et al.: A vaccine for hypertension based on virus-like particles: preclinical efficacy and Phase I safety and immunogenicity. J. Hypertens. (2007) 25(1):63-72.
60. CHACKERIANB, BRIGLIO L, ALBERT PS, LOWY DR, SCHILLER JT: Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J. Virol. (2004) 78(8):4037-4047.
61. LI Q, CAO C, CHACKERIAN B et al.: Overcoming antigen masking of anti-amyloidβ antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidβ immunized amyloid precursor protein transgenic mice. BMC. Neurosci. (2004) 5:21.
62. TSUNETSUGU-YOKOTA Y, MORIKAWA Y, ISOGAI M et al.: Yeast-derived human immunodeficiency virus Type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs. J. Virol. (2003) 77(19):10250- 10259.
63. LENZ P, DAY PM, PANG YY et al.: Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. (2001) 166(9):5346-5355.
64. LENZ P, LOWY DR, SCHILLER JT: Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur. J. Immunol. (2005) 35(5):1548-1556.
65. BUONAGURO L, TORNESELLO ML, TAGLIAMONTE M et al.: Baculovirus-derived human immunodeficiency virus Type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J. Virol. (2006) 80(18):9134-9143.
66. YE L, LIN J, SUN Y et al.: Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology (2006) 351(2):260-270.
67. GEDVILAITE A, DORN DC, SASNAUSKAS K et al.: Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. Virology (2006) 354(2):252-260.
68. BICKERTT, WOHLLEBEN G, BRINKMAN M et al.: Murine polyomavirus-like particles induce maturation of bone marrow-derived dendritic cells and proliferation of T cells. Med. Microbiol. Immunol. (Berl.) (2007) 196(1):31-39.
69. TEGERSTEDT K, FRANZEN A, RAMQVIST T, DALIANIS T: Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor. Cancer Immunol. Immunother. (2007).
70. LENZ P, THOMPSON CD, DAY PM et al.: Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin. Immunol. (2003) 106(3):231-237. An early paper demonstrating the possibility of gene transfer using polyoma VLPs.
71. FAUSCH SC, DA SILVA DM, KAST WM: Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. (2003) 63(13):3478-3482.
72. RUDOLF MP, NIELAND JD, DASILVA DM et al.: Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles. Biol. Chem. (1999) 380(3):335-340.
73. CHANG D, CAI X, CONSIGLI RA: Characterization of the DNA binding properties of polyomavirus capsid protein. J. Virol. (1993) 67(10):6327-6331.
74. GILLOCK ET, ROTTINGHAUS S, CHANG D et al.: Polyomavirus major capsid protein VP1 is capable of packaging cellular DNA when expressed in the baculovirus system. J. Virol. (1997) 71(4):2857-2865.
75. SLILATY SN, APOSHIAN HV: Gene transfer by polyoma-like particles assembled in a cell-free system. Science (1983) 220(4598):725-727.
76. FORSTOVA J, KRAUZEWICZ N, SANDIG V et al.: Polyoma virus pseudocapsids as efficient carriers of heterologous DNA into mammalian cells. Hum. Gene Ther. (1995) 6(3):297-306.
77. GOLDMANN C, STOLTE N, NISSLEIN T et al.: Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus. J. Virol. Methods (2000) 90(1):85-90.
78. KRAUZEWICZ N, STOKROVA J, JENKINS C et al.: Virus-like gene transfer into cells mediated by polyoma virus pseudocapsids. Gene Ther. (2000) 7(24):2122-2131.
79. STOKROVA J, PALKOVA Z, FISCHER L et al.: Interactions of heterologous DNA with polyomavirus major structural protein, VP1. FEBS Lett. (1999) 445(1):119-125.
80. HEIDARIS, KRAUZEWICZ N, KALANTARI M et al.: Persistence and tissue distribution of DNA in normal and immunodeficient mice inoculated with polyomavirus VP1 pseudocapsid complexes or polyomavirus. J. Virol. (2000) 74(24):11963-11965.
81. KRAUZEWICZ N, COX C, SOEDA E et al.: Sustained ex vivo and in vivo transfer of a reporter gene using polyoma virus pseudocapsids. Gene Ther. (2000) 7(13):1094-1102.
82. SOEDA E, KRAUZEWICZ N, COX C et al.: Enhancement by polylysine of transient, but not stable, expression of genes carried into cells by polyoma VP1 pseudocapsids. Gene Ther. (1998) 5(10):1410-1419.
83. MANNOVA P, FORSTOVA J: Mouse polyomavirus utilizes recycling endosomes for a traffic pathway independent of COPI vesicle transport. J. Virol. (2003) 77(3):1672-1681.
84. KIMCHI-SARFATY C, ARORA M, SANDALON Z, OPPENHEIM A, GOTTESMAN MM: High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences. Hum. Gene Ther. (2003) 14(2):167-177.
85. ARAD U, ZEIRA E, EL-LATIF MA et al.: Liver-targeted gene therapy by SV40-based vectors using the hydrodynamic injection method. Hum. GeneTher. (2005) 16(3):361-371.
86. KIMCHI-SARFATY C, VIEIRA WD, DODDS D et al.: SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice. Cancer Gene Ther. (2006) 13(7):648-657.